Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I challenge you...DR FUD...
SEE YA---GEO
great post cosmic eom...
Dr FUD.....
When ever some one posts a positve you RANT that it is a PUMP AND DUMP....
Not once have I heard an agreeance from you concerning anything posted unless it is a negative....
There for I am left with no other thought then to think you LIE TO BUY.....
WHY ELSE WOULD YOU BE HERE?....
Hmmmmmmmm---GEO
hmmmmmm......I wonder?
Even though we have validated our
DNAWITNESS technology with blind test studies through police and crime
laboratories, we are looking toward certification from the American
Society of Crime Laboratory Directors (ASCLD). We need to either qualify
for certification on our own or obtain it through acquisition. So we're
currently looking at acquisitions in general ' not only for the purpose
of obtaining ASCLD certification but we're also shopping for clinical
laboratories that could enable us to do diagnostics for the FDA.
Hi illwill.....
I'm glad to hear from ya....
GEO
DR FUD...unjustified optimism?
The Ova test is in progress with Moffitt....
Expect a 95% success rate (already stated so far)....
6 to 9 months for results....
I believe I'm justified to be optomistic....
Don't you?.....
There can be no progress if people have no faith in tomorrow
GEO
BS?......
I am waiting ......
But I will be suprised if you are still around.....
I suspect the Higher SP the less we will hear from you JMHO...
But if I'm wrong I will be hear to take it.....
But in all fairness give DNAPRINT 6 months after R/S.....
I believe 6-9 months would be a good measuring stick....
We shall see---GEO
FSAIL52...
All signs are pointing NORTH....
I to would love to have seen no R/S....
But (this is a thought) what if all went really well...
down the road we split our shares 1 to 10 or 1 to 20....
interesting thought I would think....
I am hoping that our increased distributor base will help with the financing of future endevours and not totally rely on D.BANK....
I remember my momma saying "just because it doesn't taste good doesn't mean it's not working"
Lets face it DNAP is into personalized medicine....
I beleive this is a "no brainer"---GEO
I suspect we will hear the last of ....
Dr FUD, KY-KID, TD, Frog-nightmare, tiny tony, spakle.....
It is of my opinion, that we will recieve traction as far as upward movement in PS. To much in the news to ignore or even downplay....
Funding is available.....
Super EPO work on going....
Our BED-FELLOWS are of notable recognition....
OVO testing underway with Moffitt.....
next in line statin testing?......
Starting to generate Revenue ......
So why the R/S...simple, please read the last few sentences of this statement....
We also believe the current per share price level of the common stock has reduced the effective marketability of the common stock because of the reluctance of many brokerage firms to maintain active analyst coverage of low price stocks, to recommend low price stocks to those clients or even to deal in low price stocks. Additionally, since brokerage commissions on low price stock may represent a higher percentage of the stock price than commissions on higher price stock, the current share price of the common stock can result in individual shareholders paying transaction costs (commission, markups or markdowns) representing a higher percentage of their total share value than would be the case if the share price were higher. Finally, some investors may view low price stock as speculative and unattractive, although other investors may be attracted to low price stock because of the greater trading volatility sometimes associated with such securities. Such a limited shareholder base may have the undesirable effect of artificially limiting demand for the common stock, thus depressing the stock price.
AN R/S is IMHO is the next evolution to DNAP.....
Look forward.....
Many have stated a downward trend after R/S....
I will state from what I have been observing, an upward trend....
minimal O/S is required to both protect our investments as well increase Value....IMHO
I have often seen 1000 @ .0122 when the bid is .0129 and the ask is at .0130
only to see 500,000 @ .0122 seconds later....
pure manipulation.... to many O/S available
An R/s will give investors some sort of strength.....
Value will depend on the Company and not Stock manipulators
I advocate for EVOLUTION not REVOLUTION
If, and I beleive it is, this company is to move forward we must increase awareness at other than sub-penny to be taken serious from investing institutions. ANd that my fellow friends benifits us all.....
Looking forward to hear from the prudent investors...LOL
GEO
Thanks illwill.....
BUT I am not worried....
I am more excited with the prospect of less stock manipulation
I am more excited with the prospect of more revenue...
I am more excited with the prospect of name recognition....
I am more excited with the prospect of helping millions of people....
BUT most of all I am excited I am a part owner of DNAPRINT
Thanks for your concern illwill....
All the best to those that have faith....
UP UP and AWAY---GEO
Oh how you twist things Dr FRUD.....
You have twisted what I have said.....
Which is DNAPRINT is "NOT FOR SALE".....
If The ADMIXMAP patent is received....
DNAPRINT (JMHO) will become the NASA of pharma...
If you want to launch a satillite you go to NASA...
If you want to launch a new DRUG you go to DNAPRINT...
NASA as well as DNAPRINT will increase your success rate in regards to any launch attempt....
I hope I made my point....
UP UP and AWAY----GEO
Dr FUD.......
Maybe your not to far off about a take over.....
Maybe DNAPRINT seems to agree with you, with good reason...
Soooo (just in case).....
The combination will have no effect on the total number of our authorized shares of common stock. Upon effectiveness of the combination, however, the number of authorized but unissued shares of common stock would increase from approximately 409,000,000 to between approximately 1,390,000,000 and 1,446,000,000, depending on the size of the combination. We may issue authorized but unissued shares of our common stock in our discretion. Although this increase could, under certain circumstances, have an anti-takeover affect (for example, by permitting issuances that would dilute the stock ownership of a person seeking to effect a change in the composition of the board of directors or contemplating a tender offer or other transaction for the combination of the company with another company), the combination proposal is not being proposed in response to any effort to accumulate our shares of common stock or obtain control of us, nor is it part of a plan by management to recommend a series of similar amendments to the Board of Directors and shareholders. Other than the combination proposal, the Board does not currently contemplate recommending the adoption of any other amendments to our Articles of Incorporation that could be construed to affect the ability of third parties to take over or change control of the company, nor is the combination being recommended by the Board as part of an anti-takeover strategy.
Call this the "JUST IN CASE CLAUSE"---GEO
OK ICE....
pure BS I hope means beautifull15y said....
as far as 1.5 billion shares!
I just thought I should point out they would be A/s shares
not O/S shares (yet)......
An R/S means 150 Million shares or so to represent shareholder value. Every one claims the same % as they do now....
24.1 months to receive a patent.....I said
4 to 5 yrs already.....you said
You would think then we are not far from the ADMIXMAP patent then.......
ICE.... lets say we went for a 10 for 1 R/S
Now our shares as today are .13 cents
ADMIXMAP or some other great thing like a M/A is announced...
PS raises,...lets say x3
PS = .39 cents
D.BANK accumulates $600,000 in A/S
at .39 cents a share they receive aprox. 1.5million shares
O/S now = 151.5 million shares....
What I'm saying is that All A/S shares need not be used ( I to Hope not) but as long as the O/S price increases less A/S will be needed thus minimizing the Dilution ....
After is all is said and done I am hoping for no more than x2 of O/S after R/S .....
Soooooo ICE....
sorry I wasn't more clear----GEO
A reduction in O/s shares....
10 for 1....20 for 1......
Increase in unissued shares....
higher pps = fewer issued unissued shares...
higher pps = "big news"
big news = patent
did you know it takes on average 24.1 months to receive a patent?
So if our pps were higher, then less unissued shares would be needed to be issued for helpul financing.....
hmmmm....---GEO
P.S I beleive in the "TEAM" I VOTE YES.....
On May 2, 2005, the record date with respect to this solicitation for determining stockholders entitled to notice of, and to vote at, the Annual Meeting, 1,090,893,175 shares of the Company's Common Stock were outstanding, and 40,000 shares of the Company’s Series A Preferred Stock. Only stockholders of record on such date are entitled to notice of, and to vote at, the Annual Meeting and at any adjournment thereof. Each stockholder of record is entitled to one vote for each share of Common Stock held on all matters to come before the Annual Meeting and at any adjournment thereof. A holder of one share of Series A Preferred Stock is entitled to a number of votes equal to the number of shares of Common Stock into which such share can be converted.
WHO OWNS THE PREFERRED STOCK?---GEO
Its to bad.......
That the R/S didn't come with a warrant agreement to benifiet
excisting shareholders....
I know of 40,000 prefered shares ......
With a common share value of?.......
Hmmmmm.....
IN GOD WE TRUST---GEO
And in CANADA.....
OTTAWA -- A controversial new law, that will force killers such as Karla Homolka to supply DNA samples, went into force yesterday.
Victims' advocates breathed a sigh of relief after the Senate gave the bill its final blessing - just hours before MPs voted on a budget that could have triggered an election and killed the bill.
Steve Sullivan, president of the Canadian Resource Centre for Victims of Crime, said Homolka was the "driving factor" to urgently pass the bill before her July 5 release. Given grave concerns raised by the National Parole Board that she remains a high risk, he said it makes sense to have her DNA in the bank.
But Sullivan said the merits of the new law reach far beyond the notorious sex killer.
"It means potentially over 4,000 more violent offenders in the databank, which will undoubtedly help police solve some unsolved crimes, and if any of these offenders reoffend after release, it will help police solve those crimes quicker," he said.
"This is a bill that will definitely enhance public safety in Canada."
IN GOD WE TRUST---GEO
In the new pharmacogenomics alliance, Moffitt physicians and scientists are teaming with DNAPrintTM to identify genetic variants that underlie poor patient response to various chemotherapies and also to implement new clinical tests at the Cancer Center.
These genetic variants will be combined with other biomarkers from gene-expression, proteomics and epidemiological research with the aim to predict patient chemotherapy response from the DNA before chemotherapy begins. That way, patients who are not likely to respond can be spared from exposure to ineffective therapy.
With the newly signed agreement, both organizations have teamed to make an important stride towards their goal of enabling a more personalized, safe and effective modality of cancer treatment for our current generation of cancer patients.
A primary area of focus for the effort is colorectal cancer, long a primary research interest for Yeatman, a professor of surgery in the USF Department of Interdisciplinary Oncology. Approximately 50 percent of patients fail to respond to the current FDA-approved therapy for colon cancer. Given the poor prognosis associated when therapies fail to work, there is a dire need for tools capable of predicting response beforehand, Yeatman said.
In 2001, the National Cancer Institute awarded Moffitt the status of a Comprehensive Cancer Center in recognition of its excellence in research and contributions to clinical trials, prevention and cancer control. Additionally, Moffitt is a member of the National Comprehensive Cancer Network, a prestigious alliance of the country's leading cancer centers, and is listed in the U.S. News & World Report as one of the top cancer hospitals in America.. Moffitt's sole mission is to contribute to the prevention and cure of cancer.
TWST: Tell us about the company's management and its goals for the
future.
Mr. Gabriel: We've all been working at this for some time. I've been in
the pharmaceutical business for 20 years.
Dr. Hector Gomez, our Chairman and Chief Medical Officer, has been in it
all of his life. He has 11 drugs under his belt; I have four or five and
probably have been involved with 60 or 70 ' from discovery all the way
to approval ' over the course of my career. There are three or four
drugs on the market now that have gone through my previous company's
hands. We're dedicated individuals, and I thank our shareholders for
believing in our company. And that, quite honestly, is why we're looking
for acquisitions. We want to build our revenue, and we either build our
revenue through sales, selling a new technology into a market, which is
hard, or we acquire it ' and we're aggressively looking at both because
the goal is to boost shareholder value. I myself am a shareholder.
GEO
1140@.0133.............
Who ever did this can you give me you brokers #....
I think I have to review my broker rates...LOL
SHEEESH---GEO
Heres a perfect place to help.....
Genentech [DNA] has released Phase II data indicating that its humanized monoclonal antibody (mAb) product Omnitarg had limited activity when used as a monotherapy to treat ovarian, breast and prostate cancers. The news is potentially damaging to the company's reputation for strong pipeline portfolio management and harnessed innovation.
Omnitarg (pertuzumab) failed to show a significant benefit in a range of Phase II trials. Trial data indicated that the product demonstrated a partial response or the ability to stabilize the disease in 15% of ovarian cancer patients, 8% of patients with metastatic breast cancer with low expression of HER2, and 12% of prostate cancer patients
Finding the 15%, 8%, 12%, is where we can help.....
A clearer picture, to help those that can be helped.
GEO
ann441j.....
Thank GOD you are around....
was meant as a thank-you for asking a QUE...
which I thought helped my position with FROG...
And your POSTS are excellent ....
so once again ann441j ....
Thank GOD your around....
All the best---GEO
I have found your answer FROG......
This makes perfect sense........
We are often asked why we don't issue more press releases to spread the word about the Company’s activities. As you may know, all companies in the microcap market are frequently placed in a negative light because of the unscrupulous actions of certain microcap companies that attempt to manipulate the price of their stock by issuing frequent press releases. Some of these releases are misleading, and some of them are about immaterial matters – in either case they are an attempt to generate enthusiasm for that company’s stock and to raise its price. In our view, these actions are unethical and often illegal. Because of this public perception of the microcap market, we are very conservative in our communications with the investing public. We will not allow your company to engage in such manipulative tactics. Therefore, we do not issue press releases frequently, and we do not issue them unless we believe we have something significant to say.
I guess they have had something to say recently, wouldn't you agree FROG?
It is easy being green---GEO
P.S GREEN is the colour that best represents ENVY...
Thank GOD your around....
ANN441j
GEO
I would think So....EOM
'nuclear psychiatrist'
Now that was funny.....
OK 5yrs, I can understand your impatience. But honestly how long should it take?
Curious GEO
Before I become to happy....
What do you make of this FROG?
We have completed our initial phase of research and development on a test to
determine genetic predisposition for response to the Taxol-Carboplatin drug
combination. The Taxol-Carboplatin drug combination therapy is a treatment for
breast, ovarian, prostate and other cancers. In FDA clinical trials the
Taxol-Carboplatin drug combination therapy demonstrated efficacy in only 60-70%
of patients. In preliminary trials, our therapeutic response tests were 95%
effective in distinguishing Taxol-Carboplatin responders from non-responders.
It appears that it will up the average,
don't you think Frog?
GEO
Frog......
O......
Sorry I thought that the admixmap approach was a more cost effective as well as a more decisive analysis of individual SNP's.
OPPPS SORRY ---GEO
P.S ARE YOU SURE YOU HAVEN'T BEEN INVOLVED IN ANY OF THIS BIO-SCIENCE BEFORE?
Golf Clap ADMIXMAP......
Where is everyone else in regards to DNAP technology?
Dec/03
ADMIXMAP will allow DNAPrint to identify new disease and drug response genes 10 times faster and 1,000-times less expensively than others who use existing methods. Dr. Tony Frudakis, CEO, informally announced the introduction of ADMIXMAP to attendees at the invitation-only IBM Life Science Solution Developer Conference in Boca Raton, FL, and proclaimed the Company's intent to partner collaborative services based on the platform to pharma, biotech and academia.
The development of ADMIXMAP was a culmination of years of research into population genomics structure and human ancestry conducted with Dr. Mark Shriver of the Pennsylvania State University. The primary focus of the work was to create an original type of human genome map based on validated and characterized Ancestry Informative Markers. snAIMs are Single Nucleotide Polymorphsims (SNPs) of significant allele frequency differences between the world's various continental population groups; prior to DNAPrint's work, such a map had not existed. This map is combined with other compositions and new, highly specialized analytical algorithms to constitute the ADMIXMAP platform. The platform functions by allowing a fine appreciation of population genomics structure relevant for solving complex human conditions, and it is based on a process called Mapping by Admixture Linkage Disequilibrium (MALD) or Admixture Mapping (AM).
DNA exists in a block like state, and hypothesis-free genome screens aim to inspect each of several hundred thousand of these blocks for sequence correlation with disease or drug response. A genome-wide study usually queries hundreds of genomes. Because each genotype costs about $0.50 and hundreds of thousands of genotypes need be created per genome, a typical genome study costs several tens of millions of dollars.
On the other hand, Mapping by Admixture Linkage Disequilibrium (MALD) or Admixture Mapping (AM) takes advantage of the fact that in recently admixed populations (i.e. Hispanics or African Americans, among many others), the block-like structure of DNA extends for MegaBases rather than kilobases (Chakraborty and Weiss, 1988; Stephens et al., 1994, McKeigue 1998, McKeigue et al., 2000). Because the DNA is made of a relatively small number of very large blocks, pan-genome coverage can be obtained with as few as 1,500 markers at a cost of only $1-2K per sample or a couple hundred thousand dollars per study.
March 2-6, 2005
American Society of Clinical Pharmacology and Therapeutics meeting in Orlando, Florida that using their technology platform, SNP or Single Nucleotide Polymorphism identifications of disease genes can be accomplished for about $250,000 to $500,000 per gene. Another scientist at the meeting, James Watters, PhD; Washington University: PGRN Member reiterated the earlier presentation and pointed out the isolation of 6 candidate genes sets for poor patient response to Docetaxel treatment. However, neither Watters nor McLeod were able to acknowledge a validation of their work and hinted that the six isolated genes, might in fact, not be the correct genes associated with drug metabolism. They are continuing their work using the Perlegen/Affymetrix system.
DR F......
In response to your comments I have to disagree...
No patents you say....I disagree
Technology worthless today....I disagree
(Please note the confrence in Florida yesterday and the results of the up and coming inhibators. DR T's ADMIXMAP would be a great help to these companies JMHO.)
If they don't create personolized medicine for revenue, their done......I cant argue that.
But they say they have already started work on the Super EPO...I hope thats a good thing...( Beth-Patent which we have the exclusive rights for.)
It is a beatiful day, here---GEO
Frog............Truce.......
I am no longer willing to butt heads with you...
But I am willing to discuss items .......
what do you make of the statement "more inventory" and shipping/handling clerk?.....
I find that on a tight budget wouldn't you order items "knowing" they would sell? For cash flow reasons and all that..
I am also curious about the 5 new distributors, a few I can figure out but the rest....hmmmm.
More floor space more personal...
Sure a lot of PR in the last few months...
Sure a lot of VOL as well...
I find that all of this ... is predictable for a growth CO.
But all in all I believe that the ADMIXMAP patent would represent the Horses in front of the Carraige, don't you agree.
Have a good day, Frog.---GEO
Blue.........
I've read your posts and understand were your frustrations lie as well as your loyalty....
Have a great day---GEO
receiving the patent on ADMIX.......
Would shoot us to da mooooooooooon...jmho
This patent would be the jewel in the crown. I pray we get it very soon!!!
It's a beatiful morning---GEO
R/S do they work? lets watch....
Globetel Communications Corp (OTC BB: GTEL, $0.247) has been one of
the most active OTCBB traders in 2005 and continues to show strength.
The Company announced this morning that it expects its shares will
begin trading on the American Stock Exchange under the symbol GTE on
Monday, May 23, 2005, on a post split basis. The American Stock
Exchange granted approval to their listing contingent upon the
Company affecting a 1 for 15 reverse stock split.
Que 2).......Frog
In
addition to the revenues recognized in the accompanying statement of operations,
we also have recorded deferred revenues of approximately $53,000 as of March 31,
2005. Deferred revenue resulted primarily from some ANCESTRYbyDNATM client
testing that was not complete as of March 31, 2005. These amounts will be
recognized as revenue in the second quarter of 2005.
So is it safe to say that DNAP has made around $135,000 in three month's. More than half of what it was able to generate in 2004?
CURIOUS---GEO
Que 1)....Frog
During the
first quarter of 2005, one university accounted for approximately $82,000 of our
genotyping sales during the first quarter of 2005.
Which University do you think it was?
Curious---GEO
It suggest nothing else Frog......
But I accept your knowledge to be unquestionable so I have some questions that I can't answer. WILL you help me?
IN GOD WE TRUST---GEO
OOOPS>>>EOM
fROG........
this statements seems that the first payment to beth has already been issued?
In exchange for the license, we paid Beth Israel a $25,000 signing fee and
agreed to make certain milestone payments linked to their progress in developing
marketable products from the licensed technology. The total of payments, if all
milestones are reached, is $2,150,000. The milestone payments are nonrefundable.
Up to $200,000 of this amount is creditable against future royalties. In
addition to the milestone payments, we must also pay Beth Israel an annual
royalty of 4% of the net sales of all products developed from the licensed
technology. A minimum royalty payment of $100,000 a year is due upon the
commencement of commercial sales in any territory worldwide.
Thats what I have that suggests the Beth patents are in "the bag" what have you got that implies differently?
IN GOD WE TRUST---GEO
Blue... Frog....
I'll ask both of you honestly.
What do you think will happen with those 8 patents from Beth..
Also, If you were Tony or Gabe what direction would you persue?
And, As an R/D Co. what do think of the advancement's towards incurring distributors for our forensic and ancestry kit's?
Looking forward to both of your responses, I too want understand!
To close; I am convinced this Co. is not far from their objectives. You tend to recite the past as if you can't look forward. Not trying to be rude just observant.
IN GOD WE TRUST---GEO